

# Conformational Rearrangements and Signaling Cascades Involved in Ligand-Biased Mitogen-Activated Protein Kinase Signaling through the $\beta$ 1-Adrenergic Receptor

Ségolène Galandrin, Geneviève Oligny-Longpré, Hélène Bonin, Koji Ogawa, Céline Galés,<sup>1</sup> and Michel Bouvier

*Department of Biochemistry and Groupe de Recherche Universitaire sur le Médicament, Institute for Research in Immunology and Cancer, Université de Montréal, Montréal, Québec, Canada*

Received December 6, 2007; accepted April 2, 2008

## ABSTRACT

In recent years, several studies have demonstrated that different ligands can have distinct efficacy profiles toward various signaling pathways through a unique receptor. For example,  $\beta$ 1-adrenergic compounds that are inverse agonists toward the adenylyl cyclase (AC) can display agonist activity for the mitogen-activated protein kinase (MAPK) pathway. Such a phenomenon, often termed functional selectivity, has now been clearly established for many G protein-coupled receptors when considering distinct signaling output. However, the possibility that ligands could selectively engage distinct effectors to activate a single signaling output by promoting specific receptor conformations has not been extensively examined. Here, we took advantage of the fact that isoproterenol, bucindolol and propranolol (full, partial, and inverse agonists for the AC pathway, respectively) all activate MAPK through the  $\beta$ 1-adrenergic re-

ceptor ( $\beta$ 1AR) to probe such conformational-biased signaling. Although the three compounds stimulated MAPK in a src-dependent manner, isoproterenol acted through both  $G_{\alpha\beta\gamma}$ - and G protein-independent pathways, whereas bucindolol and propranolol promoted MAPK activation through the G protein-independent pathway only. The existence of such distinct signaling cascades linking  $\beta$ 1AR to MAPK activation was correlated with ligand-specific conformational rearrangements of receptor/G protein complexes measured by bioluminescence resonance energy transfer. Taken together, our data indicate that discrete local conformational changes can selectively promote the recruitment of distinct proximal signaling partners that can engage distinct signaling outputs and/or converge on the same signaling output.

G protein-coupled receptors (GPCRs) represent the most prevalent class of transmembrane signaling proteins. They can modulate a large variety of signaling systems to ensure a fine regulation of cell function in response to external stimuli. This signaling diversity is achieved in part by the capac-

ity of one receptor to couple to diverse G proteins and non-G protein effectors (Bockaert et al., 2004). Over the past decade, many studies have demonstrated that different subsets of these effector systems can be selectively modulated by distinct ligands through a unique receptor, a phenomenon often referred to as ligand-biased signaling (Galandrin et al., 2007; Kenakin, 2007). Hence, efficacy of GPCR ligands is increasingly considered as a pluridimensional parameter that should include in its definition, in addition to the ligand/receptor pair, the signaling pathways considered.

Characterizing a panel of  $\beta$ -adrenergic ligands for their efficacy profiles toward two of the  $\beta$ 1-adrenergic receptor ( $\beta$ 1AR)-stimulated signaling pathways, adenylyl cyclase (AC) and mitogen-activated protein kinase (MAPK) path-

This work was supported by grants from the Canadian Institute for Health Research (CIHR) and the Québec Heart and Stroke Foundation. G.O.-L. was supported by a studentship from the CIHR; K.O. was an invited researcher from Tanabe Seiyaku Co. Ltd.; and M.B. holds a Canada Research Chair in Signal Transduction and Molecular Pharmacology.

C.G. and M.B. contributed equally to this work.

<sup>1</sup> Current affiliation: Institut National de la Santé et de la Recherche Médicale U858-I2MR-Equipe 8, Toulouse, France.

Article, publication date, and citation information can be found at <http://molpharm.aspetjournals.org>.  
doi:10.1124/mol.107.043893.

**ABBREVIATIONS:** GPCR, G protein-coupled receptor;  $\beta$ AR,  $\beta$ -adrenergic receptor; AC, adenylyl cyclase; MAPK, mitogen-activated protein kinase; ERK, extracellular signal-regulated kinase; BRET, bioluminescence resonance energy transfer; AVP, arginine 8 vasopressin; PP2, 4-amino-5-(4-chlorophenyl)-7-(*t*-butyl)pyrazolo[3,4-*d*]pyrimidine; PD98059, 2'-amino-3'-methoxyflavone; EGF, epidermal growth factor; CTX, cholera toxin B; PTX, pertussis toxin; PKA, protein kinase A; HRP, horseradish peroxidase; GFP, green fluorescent protein; GFP10, blue-shifted mutant of green fluorescent protein;  $\beta$ ARK,  $\beta$ -adrenergic receptor kinase; HEK, human embryonic kidney;  $\delta$ OR,  $\delta$  opioid receptor; V2R, vasopressin type 2 receptor; PTH, parathyroid hormone; siRNA, small interfering RNA; PBS, phosphate-buffered saline; Rluc, *Renilla reniformis* luciferase; TBS-T, Tris-buffered saline/Tween 20; p-, phospho; MEK, mitogen-activated protein kinase kinase.

ways, we found that compounds displaying opposite efficacy toward AC shared common agonistic activity for MAPK. Indeed, isoproterenol, bucindolol, and propranolol that are, respectively, full agonist, partial agonist, and inverse agonists for AC were found to act as agonists for the extracellular signal-regulated kinase (ERK) 1/2 pathway (Galandrin and Bouvier, 2006). The inverse efficacy of propranolol compared with bucindolol and isoproterenol for  $\beta$ 1AR-stimulated AC clearly reveals the ability of the compounds to promote distinct receptor conformations. Because the three compounds activate MAPK, the data indicate that distinct receptor conformations can converge on the stimulation of a single downstream effector system.

Multiple pathways have been shown to link GPCR to MAPK activation. Some of these involve the generation of second messengers resulting from classic G protein activation, whereas others rely on the scaffolding properties of proteins such as  $\beta$ arrestin (Luttrel, 2005). However, the correlation between the signaling cascades leading to MAPK and specific receptor conformation that can be promoted by different ligands has not been established yet. We therefore took advantage of the fact that isoproterenol-, bucindolol-, and propranolol-promoted receptor conformations converged on ERK1/2 stimulation to link receptor conformations to specific effector cascades. For this purpose, the pathways leading to the  $\beta$ 1AR-mediated activation of ERK1/2 were investigated for the three ligands, whereas the conformations of the liganded receptor were assessed by bioluminescence resonance energy transfer (BRET) measurements monitoring structural rearrangements within receptor/G protein complexes. We report that isoproterenol stimulated ERK1/2 through both  $G_i$ -dependent and G protein-independent mechanisms, whereas bucindolol and propranolol engaged MAPK only via the G protein-independent pathway. Note that the distinct signaling pattern of isoproterenol was associated with a unique conformational signature of the receptor/G protein complex, confirming that distinct ligands can select different signaling cascades by promoting discrete conformational rearrangements.

## Materials and Methods

**Reagents.** (-)-Isoproterenol, DL-propranolol, Leu-enkephalin, and arginine-8 vasopressin (AVP) were purchased from Sigma-Aldrich (St. Louis, MO), whereas bucindolol was a generous gift from Dr. Michael Bristow (University of Colorado Health Sciences Center, Aurora, CO). Recombinant human epidermal growth factor (EGF) was from PeproTech (Rocky Hill, NJ). Cholera toxin B subunit (CTX) and pertussis toxin (PTX) were from Sigma-Aldrich. Inhibitors PP2 and PD98059 were from Calbiochem (San Diego, CA). Mouse anti-phosphorylated ERK1/2, rabbit anti-ERK1/2, and anti- $\beta$ arrestin2 (H9) antibodies were from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA). Antibody recognizing the phosphor-(Ser/Thr) protein kinase A (PKA) substrate was purchased from Cell Signaling Technology Inc. (Danvers, MA). HRP-anti-mouse and HRP-anti-rabbit polyclonal antibodies were from GE Healthcare (Baie d'Urfé, QC, Canada). All other reagents were of analytical grade, and they were obtained from various suppliers.

**Expression Vectors.** The plasmid encoding rat ERK2-GFP (DeFea et al., 2000b) and the  $\beta$ -adrenergic receptor kinase ( $\beta$ ARK) carboxyl-terminal (C)-tail conjugated to the extracellular and transmembrane domain of the CD8 protein (T8 $\beta$ ARKctail) (Crespo et al., 1995) were generous gifts from K. DeFea (University of California, Riverside, CA) and J. S. Gutkind (National Institutes of Health,

Bethesda, MD), respectively. Plasmid encoding  $\beta$ arrestin1 deleted in its C-tail from amino acid 319 to amino acid 418 ( $\beta$ -Arr  $\Delta$ 318-419) was generously provided by Jeffrey L. Benovic (Thomas Jefferson University, Philadelphia, PA). Plasmids encoding the  $\beta$ 1-adrenergic receptor fused to its C terminus with humanized *Renilla reniformis* luciferase ( $\beta$ 1AR-hRLuc) or the blue variant of GFP ( $\beta$ 1AR-GFP10) were described previously (Mercier et al., 2002). The expression vectors containing human G protein subunits ( $G_{\alpha_{11}}$ ,  $G_{\gamma_2}$ , and  $G_{\beta_1}$ ) were obtained from Missouri University of Science and Technology (Rolla, MO). Plasmids encoding  $G_{\gamma_2}$  fused at its N terminus to GFP10 (GFP10- $G_{\gamma_2}$ ) or  $G_{\alpha_{11}}$  tagged with hRLuc inserted between residues L91 and K92 ( $G_{\alpha_{11}}$ -91hRLuc) were described previously (Galés et al., 2006).

**Stables Cell Lines and Transfections.** HEK293S cells (Reeves et al., 1996) stably expressing the hemagglutinin-tagged human  $\beta$ 1AR, the human  $\delta$ -opioid receptor tagged with FLAG ( $\delta$ OR), or the myc-tagged V2 vasopressin receptor (V2R) were described previously (Petaja-Repo et al., 2000; Galandrin and Bouvier, 2006; Charest et al., 2007). Cells were grown in Dulbecco's modified Eagle's medium supplemented with 5% fetal bovine serum, 100 U/ml penicillin and streptomycin, 2 mM L-glutamine, and 200  $\mu$ g/ml G418, in a 37°C humidified 5% CO<sub>2</sub> atmosphere. For all BRET experiments, HEK293 cells were transiently transfected with the indicated BRET partners (tagged receptor and/or tagged G protein subunits) along with the complementary untagged G protein subunits, so to maintain the stoichiometric expression of the  $G_{\alpha_{11}}\beta_1\gamma_2$  heterotrimer. For ERK phosphorylation assays, cells were transfected in six-wells plates, and they were harvested 48 h after transfection. In all cases, transient transfections were performed using the FuGENE 6 transfection reagent (Roche Diagnostics, Indianapolis, IN) according to the manufacturer's protocol. The previously described siRNAs for  $\beta$ arrestin 1 and 2 (Ahn et al., 2003) were purchased from QIAGEN and transfected at 400 nM final concentration (300 nM  $\beta$ arrestin 1 siRNA and 100 nM  $\beta$ arrestin 2 siRNA) using the RNAiPect transfection Reagent (QIAGEN, Mississauga, ON, Canada), according to the manufacturer's protocol.

**Quantification of cAMP Accumulation.** Agonist induced cAMP accumulation was measured as described previously (Galandrin and Bouvier, 2006). Cells were grown in 60-mm dishes, and they were incubated for 16 h in Dulbecco's modified Eagle's medium, with or without 300 ng/ml CTX when indicated. The day of the experiment, cells were resuspended in PBS/0.1% glucose/1 mM 3-isobutyl-1-methylxanthine and treated for 20 min at 37°C with the indicated drugs. Propranolol was tested in the presence of 0.3  $\mu$ M forskolin to increase the signal-to-noise ratio for detecting inhibition, because it has been described as an inverse agonist. After drug treatment, cells were immediately lysed, and cAMP levels were measured using the Catch Point cAMP kit (Molecular Devices, Sunnyvale, CA), according to the manufacturer's recommendations. In brief, cells lysates were incubated in 384-well plates coated with anti-cAMP antibodies in the presence of known amounts of HRP-cAMP. cAMP from cell lysates was allowed to compete with the HRP-cAMP for 2 h, and the remaining peroxidase activity was measured after three washes. The cAMP generated under the different conditions was interpolated from a cAMP standard curve generated in parallel for each experiment. Triplicates were used for each condition, and all experiments were repeated at least three times.

**Western Blotting.** Cells expressing  $\beta$ 1AR,  $\delta$ OR, or V2R were seeded in poly-D-lysine-coated six-well plates. The next day, cells were washed once with PBS, and they were rendered quiescent by serum starvation for 16 h. Cells (~80% confluence) were then stimulated at 37°C with conditions corresponding to the maximal response obtained from time course and dose-response experiments: 4 min with 10  $\mu$ M isoproterenol, 2 min with 10  $\mu$ M bucindolol or propranolol, 5 min with 1  $\mu$ M AVP or Leu-enkephalin, or 10 min with 1 ng/ml EGF. To terminate the stimulation, the media were rapidly removed, and cells were placed on ice and washed with ice-cold PBS before being lysed using 100  $\mu$ l/well Laemmli sample buffer (6.2.5

mM Tris-HCl, 2% SDS, 10% glycerol, 50 mM dithiothreitol, and 0.1% bromophenol blue, pH 6.8). Whole cell lysates were sonicated, resolved by SDS-polyacrylamide gel electrophoresis, and transferred to nitrocellulose. The blots were then blocked at room temperature for 1 h with TBS-T buffer [50 mM Tris, pH 7.4, 150 mM NaCl, and 0.1% (v/v) Tween 20] containing 5% fat-free milk. Phospho-ERK1/2 or -ERK2-GFP were detected using mouse polyclonal anti-phospho p42/p44 ERK-specific antibody (1:3000, overnight at 4°C in TBS-T/5% fat-free milk). The immunoreactivity was revealed using a secondary HRP-conjugated anti-mouse antibody (1:10,000, 1 h at room temperature in TBS-T/5% fat-free milk), and the peroxidase activity was detected by chemiluminescence (PerkinElmer Life and Analytical Sciences, Waltham, MA). Blots were stripped and reprobed for total ERK using rabbit polyclonal anti-ERK1/2 antibody (1:25,000, 1 h at room temperature in TBS-T/5% fat-free milk) followed by HRP-anti-rabbit antibody (1:20,000, 1 h at room temperature in TBS-T/5% fat-free milk). Films were scanned, and band intensities were quantified using Quantity One software (Bio-Rad, Hercules, CA). ERK1/2 or ERK2-GFP phosphorylation was normalized according to the loading of proteins by expressing the data as a percentage of P-ERK1/2/ERK1/2 total (or P-ERK2-GFP/ERK2-GFP total) of the level observed in agonist-stimulated condition. When using P-ERK2-GFP, because a basal activity was detectable, it was not subtracted from the ligand-promoted ERK activity. Phosphorylation of PKA substrates was revealed using a rabbit polyclonal anti-P-SPKA antibody, detecting proteins containing a phosphor-Ser/Thr residue with arginine at the -3 position (1:1000, overnight at 4°C in TBS-T/5% bovine serum albumin), followed by anti-rabbit HRP-conjugated IgG (1:10,000, 1 h at room temperature in TBS-T/5% fat-free milk). Detection of  $\beta$ arrestin1 and -2 was achieved using the mouse monoclonal anti- $\beta$ arrestin2 (H9) antibody, which recognizes both  $\beta$ arrestin isoforms (1:1000, overnight at 4°C in TBS-T/0.5% fat-free milk), followed by anti-mouse HRP-conjugated IgG (1:5000, 1 h at room temperature in TBS-T/0.5% fat-free milk).


**Bioluminescence Resonance Energy Transfer Measurement.** *Rluc*- and GFP10-tagged receptor or G protein constructs were transiently transfected into HEK293 cells. Forty-eight hours after transfection, cells were washed twice with PBS, detached with PBS/5 mM EDTA, and resuspended in PBS/0.1% (w/v) glucose at room temperature. Cells were then distributed (50  $\mu$ g of protein per well) in a 96-well microplate (Optiplate; PerkinElmer Life and Analytical Sciences) and incubated in the presence or absence of the different ligands for 1 min. BRET between *Rluc* and GFP10 was measured after the addition of the *Rluc* substrate DeepBlueC coelenterazine (5  $\mu$ M) (PerkinElmer Life and Analytical Sciences). BRET<sup>2</sup> readings were collected using a modified TopCount NXT apparatus (customized version purchased from BioSignal Packard, Inc., now; PerkinElmer Life and Analytical Sciences) that allows sequential integration of signals detected in the 370- to 450- and 500- to 530-nm windows, using filters with the appropriate band pass (Chroma Technology Corp., Brattleboro, VT). The BRET signal was calculated as the ratio of the light emitted by GFP10 (510–550 nm) over the light emitted by *Rluc* (460–500 nm).

**Statistical Analysis.** Statistical analysis and curve fitting were done using Prism 3.01 (GraphPad Software, San Diego, CA). Statistical significance of the differences was assessed using one-way analysis of variance and post hoc Bonferroni's test. In some cases, one-way analysis of variance followed by Dunnett's test was used to determine statistically significant differences from basal.

## Results

**Ligand Profiles.** HEK293 cells stably expressing the human  $\beta$ 1AR were generated as described previously (Galandrin and Bouvier, 2006). The ability of the three selected compounds to modulate the AC and ERK1/2 pathways was first assessed to confirm their reported activity toward these

two signaling pathways. As reported previously (Galandrin and Bouvier, 2006), isoproterenol is an efficacious agonist toward AC, whereas bucindolol behaves as a partial agonist, reaching approximately one third of the maximal isoproterenol-promoted response (Fig. 1A). Propranolol for its part acted as an inverse agonist, leading to an inhibition of the forskolin-induced cAMP accumulation (Fig. 1B). These compounds were next evaluated in the same cells on the ERK1/2 pathway. As shown in Fig. 1C, the three compounds promoted ERK1/2 activation, with isoproterenol being the most efficacious ligand and bucindolol and propranolol acting as equivalent partial agonists. Thus, two efficacy profiles could be distinguished. Isoproterenol and bucindolol behaved as



**Fig. 1.** Profiles of the different ligands on the  $\beta$ 1AR adenylate cyclase and ERK1/2 pathways. cAMP accumulation experiments were performed in HEK293 cells stably expressing  $\beta$ 1AR.  $E_{\max}$  values were tested using a 10  $\mu$ M concentration of the indicated ligands, without (A) or with (B) 0.3  $\mu$ M forskolin. Data are expressed as -fold increase or decrease of cAMP accumulation over basal conditions. cAMP content under basal conditions were 3.94 ± 0.56 pmol/10<sup>6</sup> cells (A) and 8.02 ± 0.48 pmol/10<sup>6</sup> cells (B). Data represent the mean ± S.E. of at least three experiments performed in triplicates. C, serum-starved HEK293 cells stably expressing  $\beta$ 1AR were stimulated at 37°C with 10  $\mu$ M isoproterenol (4 min), 10  $\mu$ M propranolol, or 10  $\mu$ M bucindolol (2 min). Cells were then lysed in Laemmli sample buffer and subjected to SDS-polyacrylamide gel electrophoresis. MAPK activity was detected by Western blot using a phospho-specific anti-ERK1/2 antibody (p-ERK1/2). Expression level of ERK1/2 was controlled using an antibody directed against the total kinase population (ERK1/2), and data are expressed as a percentage of pERK/ERK of the level observed in isoproterenol-stimulated conditions. Data represent the mean ± S.E. of at least three independent experiments.

agonists for the two signaling pathways, whereas propranolol displayed an opposite efficacy profile, being an inverse agonist for the AC pathway but a partial agonist in stimulating ERK1/2 phosphorylation. No response was observed for any of the three compounds in untransfected HEK293 cells, confirming that the ligand-promoted AC and ERK modulation are  $\beta$ 1AR-mediated (data not shown). The distinct efficacy profiles observed for the two pathways are not an idiosyncrasy of the cell line selected because similar results were obtained in cells transiently expressing the  $\beta$ 1AR.


**Involvement of Heterotrimeric G Proteins.** To determine whether three compounds displaying distinct efficacies toward AC (full agonist, isoproterenol; partial agonist, bucindolol; and inverse agonist, propranolol) can engage distinct ERK1/2 activation mechanisms, the effector systems specifically stimulated by the ligand-bound receptor for the activation of the MAPK pathway were investigated. The potential implication of  $G\alpha$  proteins was first examined. To test the role of  $G\alpha_s$ , we subjected HEK293 cells stably expressing the human  $\beta$ 1AR to a sustained treatment with CTX, an approach that was described previously to down-regulate  $G\alpha_s$  in HEK293 cells (Seidel et al., 1999; Charest et al., 2007). The CTX-promoted knockdown of  $G\alpha_s$  was confirmed by the observed inhibition of isoproterenol-induced cAMP accumulation and PKA substrate phosphorylation (Fig. 2, inset). ERK1/2 phosphorylation stimulated by isoproterenol, propranolol, and bucindolol remained unaffected by the CTX-promoted knockdown of  $G\alpha_s$  (Fig. 2), indicating that  $G\alpha_s$  engagement is not necessary for ERK1/2 activation by any of the ligands.

Because several  $G\alpha_s$ -coupled receptors, notably the  $\beta$ 1- and  $\beta$ 2AR, were shown to promote ERK1/2 activation through a switch of coupling from  $G\alpha_s$  to  $G\alpha_i$  (Daaka et al., 1997; Martin et al., 2004), the contribution of  $G\alpha_i$  to the isoproterenol-, bucindolol- and propranolol-promoted ERK1/2 activation was evaluated. The selective inhibition of  $G_{i/o}$  signaling by PTX treatment partially blocked the isoproterenol-mediated

ERK1/2 activation, but it did not affect either bucindolol- or propranolol-stimulated ERK1/2 activity (Fig. 3A). Note that the inhibition of isoproterenol-stimulated ERK1/2 phosphorylation by the PTX treatment was not complete, leaving 30% of the response unaffected (Fig. 3A). This residual response did not result from an incomplete inhibition of  $G_i$  because the same PTX treatment fully blocked Leu-enkephalin-promoted MAPK stimulation through the  $G\alpha_i$ -coupled  $\delta$ OR (Fig. 3A, inset). These results suggest that isoproterenol relies on  $G\alpha_i$  protein to promote ERK1/2 activation, whereas bucindolol and propranolol do not.

The  $G\alpha_i$  contribution to isoproterenol- but not bucindolol- or propranolol-stimulated ERK1/2 activation was confirmed by directly assessing the ability of the compounds to activate  $G\alpha_i$ . For that purpose, we took advantage of a BRET-based assay monitoring the interaction between  $G\alpha_{i1}$ -hRluc and GFP10-G $\gamma_2$  fusion proteins, a BRET pair that was previously shown to reflect G protein activation (Galés et al., 2005, 2006). As shown in Fig. 3B, stimulation of  $\beta$ 1AR with isoproterenol led to a decrease in BRET between  $G\alpha_{i1}$ -hRluc and GFP10-G $\gamma_2$ , reflecting a separation between  $G\alpha_{i1}$  and  $G\beta\gamma$  subunits that is characteristic of G protein activation. In contrast, no BRET signal modulation was observed when cells were stimulated with bucindolol or propranolol, suggesting that these two compounds are unable to promote  $G\alpha_{i1}$  activation.

Because  $G\alpha$  and  $G\beta\gamma$  protein subunits are known to engage distinct effectors to activate MAPK (Crespo et al., 1994; Neves et al., 2002), the potential role of  $G\beta\gamma$  in the isoproterenol-, bucindolol-, and propranolol-mediated ERK1/2 activation was also evaluated. For this purpose, we took advantage of the previously described  $G\beta\gamma$  scavenger consisting of the C-tail of GRK2 ( $\beta$ ARK) conjugated to the extracellular and transmembrane domains of the CD8 protein that provides a membrane anchor for the C-tail of  $\beta$ ARK (T8 $\beta$ ARKtail) (Crespo et al., 1995). Coexpression of this scavenger of  $G\beta\gamma$  with ERK2-GFP significantly inhibited iso-




**Fig. 2.**  $G\alpha_s$  is not involved in the ERK1/2 signaling cascades promoted by the three ligands. Serum-starved HEK293 cells stably expressing  $\beta$ 1AR were pretreated or not with 300 ng/ml CTX for 16 h before stimulation at 37°C with 10  $\mu$ M isoproterenol (4 min), 10  $\mu$ M propranolol, or 10  $\mu$ M bucindolol (2 min). ERK1/2 activation was detected and quantified as described in Fig. 1C. Inset, isoproterenol-induced cAMP accumulation (top) and PKA substrate phosphorylation (bottom). Absolute value for cAMP content under control conditions was  $4.96 \pm 1.18$  pmol/ $10^6$  cells. Data represent the mean  $\pm$  S.E. of at least three independent experiments. Statistical significance of the differences was assessed using one-way analysis of variance and post hoc Bonferroni test, \*\*,  $p < 0.01$ .

proterenol-stimulated ERK2-GFP activity (Fig. 4A). In contrast, the  $G\beta\gamma$  scavenger did not inhibit the bucindolol- and propranolol-stimulated ERK1/2, but rather it increased this response (Fig. 4A), demonstrating that  $G\beta\gamma$  activation is not required for these two ligand-promoted responses. Such transient cotransfection protocol tended to increase the detected basal ERK activity differentially in the presence and absence of the dominant-negative mutants. This precluded us from subtracting the basal ERK activity as was done in other experimental conditions in which it was found to be marginal. The basal are shown as percentage of isoproterenol-stimulated activity. This rise in MAPK basal activity upon  $G\beta\gamma$  sequestration may be due to increased receptor surface expression resulting from a reduction in GRK-promoted phosphorylation and endocytosis, thus leading to detectable spontaneous activity. Similar effects were also seen after  $\beta$ arrestin knockdown (Fig. 5). The potentialization of propranolol- and bucindolol-stimulated ERK1/2 activation upon T8- $\beta$ ARKctail expression is consistent with this notion.

Note that the  $G\beta\gamma$  sequestration led to a partial blockade of the isoproterenol-stimulated ERK1/2 as was observed after

PTX treatment, suggesting a major contribution of the  $G\beta\gamma$  subunits originating from  $G_i$  in the isoproterenol-stimulated MAPK activation. The persistence of some ERK1/2 activity after  $G\alpha_i/G\beta\gamma$  inactivation indicates the contribution of a  $G_i$ -independent component to the isoproterenol-stimulated response. As shown in Fig. 4B, the maximal ERK1/2 stimulation induced by isoproterenol in the absence of PTX was reached after 4 min, whereas the maximal response of bucindolol and propranolol peaked at 2 min. Removal of the  $G_i$  component by PTX shifted the time course of the isoproterenol-stimulated ERK1/2 response so that it became similar to the kinetic profiles observed for bucindolol and propranolol. These data indicate that two kinetically distinct components contribute to the isoproterenol-stimulated response: a late component (peaking at 4 min) that most likely reflects the  $G_i$ -dependent response, and a more rapid  $G_i$ -independent phase (peaking at 2 min) that may also be shared by bucindolol and propranolol.

**Involvement of the Scaffolding Protein  $\beta$ Arrestin.** In addition to their role in receptor desensitization and internalization,  $\beta$ arrestins are now known to scaffold members of




the MAPK signaling cascade and to contribute to some GPCR-mediated MAPK activation (Luttrell et al., 1999; DeFea et al., 2000a; McDonald et al., 2000; Miller et al., 2000; Luttrell et al., 2001). Hence, to test their involvement in isoproterenol-, bucindolol-, and propranolol-induced ERK1/2 stimulation, we used a C-tail truncated form of  $\beta$ arrestin 1 ( $\beta$ arr  $\Delta$ 318-419) as a dominant-negative for  $\beta$ arrestin. Overexpression of this construct in cells stably expressing V2R, a receptor described previously to activate ERK1/2 via  $\beta$ arrestin (Charest et al., 2007), significantly decreased the AVP-induced ERK1/2 stimulation (Fig. 5A, inset), confirming the dominant-negative activity of  $\beta$ arr  $\Delta$ 318-419. However, using the same conditions, ERK1/2 response induced by isoproterenol, bucindolol, and propranolol was not affected by the  $\beta$ arrestin dominant-negative mutant (Fig. 5A). Of notice, as was the case in the T8- $\beta$ ARKctail cotransfection experiments, the basal ERK1/2 activity observed in the experiments testing the role of  $\beta$ arrestin tended to be elevated. This, most likely, results from the fact that, to properly assess the effects of the dominant-negative constructs, ERK2-GFP needed to be cotransfected, leading to an in-

creased basal signal resulting from its intrinsic activity. As a consequence, the bucindolol- and propranolol-stimulated responses were smaller than those observed in the absence of ERK2-GFP expression.

The lack of involvement of  $\beta$ arrestin in the  $\beta$ 1AR-stimulated ERK1/2 response was further confirmed by the observation that intracellular depletion of both  $\beta$ arrestin isoforms (Fig. 5B, inset), using siRNAs, did not inhibit ERK1/2 phosphorylation promoted by the three ligands (Fig. 5B). Of notice, both siRNA and dominant-negative approaches targeting  $\beta$ arrestins led to a potentiation of the  $\beta$ 1AR-promoted MAPK response, most likely resulting from an increased receptor cell surface density as a consequence of a blunted  $\beta$ arrestin-mediated endocytosis. Note that the increases observed in ERK1/2 activity upon  $\beta$ arrestin depletion were not proportional to the responses elicited by each ligand in normal conditions; propranolol and bucindolol stimulation led to a level of ERK1/2 activation similar to that of isoproterenol upon knockdown of  $\beta$ arrestins. The smaller relative potentiating effect on the isoproterenol response may result from a saturation of the response for the full agonist as a consequence of limited signaling partners in the context of the increased cell surface receptor.

**Involvement of the Src and MEK Kinases.** Because several studies documented the role of Src tyrosine kinase proteins in GPCR-mediated MAPK activation (Luttrell et al., 1999; Cao et al., 2000; DeFea et al., 2000a; Charest et al., 2007), we sought to determine whether this cytosolic kinase family was involved in  $\beta$ 1AR-mediated ERK1/2 activation induced by isoproterenol, bucindolol, and propranolol. For that purpose, we assessed the effect of Src family proteins tyrosine kinase inhibition using the selective inhibitor PP2. As shown in Fig. 6A, such treatment almost completely blocked isoproterenol-, bucindolol-, and propranolol-stimulated ERK1/2 activity, suggesting that Src tyrosine kinase proteins play a key role in the MAPK signaling cascades promoted by the three compounds. For isoproterenol, the extensive inhibition of ERK1/2 activation upon PP2 treatment indicates that Src is involved in both  $G_i$ -dependent and -independent  $\beta$ 1AR-mediated MAPK stimulation. Likewise, the inhibition of the penultimate kinase involved in the prototypical ERK1/2 signaling cascade, MEK, completely blocked the response promoted by the three ligands (Fig. 6B), suggesting the convergence of the  $G_i$ -dependent and -independent pathways.

**Linking Receptor Conformational Changes to Signaling Efficacy.** The above-mentioned data indicate that, apart from having different efficacy profiles toward AC and MAPK pathways, isoproterenol, bucindolol, and propranolol also differ in their ability to engage  $G_i$ , the MAPK activation being partially  $G_i$ -dependent for isoproterenol but  $G_i$ -independent for bucindolol and propranolol. Such ligand-selective behavior, variously referred to as "ligand-directed trafficking of receptor stimulus," "collateral efficacy," "ligand-biased signaling," or "functional selectivity," is believed to originate from distinct ligand-promoted conformational reorganization of the receptor (Galandrin et al., 2007). To directly probe the link between the conformations and the functional selectivity promoted by the three ligands, we took advantage of a BRET-based assay to monitor structural rearrangement within receptor/G protein complex (Galés et al., 2006). This receptor/G protein




**Fig. 4.**  $G\beta\gamma$  engagement is required for isoproterenol- but not bucindolol- and propranolol-stimulated ERK1/2 activity. A, cells stably expressing  $\beta$ 1AR were cotransfected with ERK2-GFP and either T8 $\beta$ ARKctail (the dominant negative of  $G\beta\gamma$ , +) or pcDNA3.1 (-), and serum-starved before activation at 37°C with 10  $\mu$ M isoproterenol (4 min), 10  $\mu$ M propranolol, or 10  $\mu$ M bucindolol (2 min). Expression of total and phosphorylated ERK2-GFP was detected and quantified as described in Fig. 1C. Statistical significance of the differences was assessed using one-way analysis of variance and post hoc Bonferroni's test; \*,  $p < 0.05$ ; \*\*\*,  $p < 0.001$ . B, serum-starved HEK293 cells stably expressing  $\beta$ 1AR were pretreated or not with 100 ng/ml PTX for 16 h before stimulation at 37°C with 10  $\mu$ M isoproterenol, 10  $\mu$ M propranolol, or 10  $\mu$ M bucindolol for the indicated time. ERK1/2 activation was detected and quantified as described in Fig. 1C. Data represent the mean  $\pm$  S.E. of at least three independent experiments.

BRET sensor was previously demonstrated to reflect ligand-induced conformational rearrangements leading to changes in the distance between the receptor carboxyl tail and either  $G\alpha$  or  $G\gamma$ . As shown in Fig. 7A, stimulation of the  $\beta$ 1AR with isoproterenol increased the BRET between  $\beta$ 1AR-hRLuc and GFP10- $G\gamma$ 2 in the presence of untagged  $G\alpha_i$ , which was selected rather than  $G\alpha_s$  because of its differential involvement in the  $\beta$ 1AR-mediated MAPK activation. In the same conditions, bucindolol and propranolol both decreased the BRET signal between the two partners. Similar results were obtained when BRET was measured between  $G\alpha_{i1}$ -hRLuc and  $\beta$ 1AR-GFP10 (Fig. 7B), indicating that isoproterenol promoted a conformational state of the  $\beta$ 1AR that is distinct from those induced by bucindolol and propranolol. However, it was not possible to distinguish the specific conformational rearrangements promoted by bucindolol and propranolol, even when BRET was measured between  $\beta$ 1AR-hRLuc and GFP10- $G\gamma$ 2 in the presence of untagged  $G\alpha_s$  or between  $G\alpha_s$ -hRLuc and  $\beta$ 1AR-GFP10 (data not shown).

## Discussion

The three  $\beta$ AR ligands tested in the present study displayed distinct efficacy profiles toward AC and MAPK, confirming the existence of functional selectivity for  $\beta$ 1AR ligands (Galandrin and Bouvier, 2006). Whereas isoproterenol, bucindolol, and propranolol behaved as full, partial, and inverse agonists, respectively, on AC, the three compounds are agonists on MAPK. An additional level of selectivity was revealed when the signaling cascades leading to ERK1/2 activation were examined. The partial agonists bucindolol and propranolol activated ERK1/2 in a  $G_i$ -independent manner, whereas both  $G_i$ -dependent and -independent pathways contributed to the isoproterenol-stimulated response, indicating that different ligands can recruit distinct subsets of signaling effectors to activate a single pathway. This is reminiscent of few other cases where distinct effectors were selectively engaged by different ligand/receptor pairs to stimulate a common downstream signaling integrator. For example, whereas PTH1-34 was found to activate MAPK through both  $G_s$  and  $\beta$ arrestin, PTH7-34 and PTHrp1-36 en-




**Fig. 5.**  $\beta$ Arrestin is not involved in the ERK1/2 signaling cascades promoted by the three ligands. **A**, cells stably expressing the  $\beta$ 1AR or the V2R (inset) were cotransfected with ERK2-GFP and either  $\beta$ arrestin1  $\Delta$ 318-419 (+) or pcDNA3.1 (-), and serum-starved before stimulation at 37°C with 10  $\mu$ M isoproterenol (4 min), 10  $\mu$ M propranolol, or 10  $\mu$ M bucindolol (2 min), or 1  $\mu$ M AVP (5 min). Expression of total and phosphorylated ERK2-GFP was detected and quantified as described in Fig. 1C. Statistical significance of the differences was assessed using one-way analysis of variance and post hoc Bonferroni's test; \*\*\*,  $p < 0.001$ . **B**, HEK293 cells stably expressing  $\beta$ 1AR were transfected with siRNAs targeting both  $\beta$ arrestin isoforms or nonspecific siRNA (-), and they were serum-starved before stimulation at 37°C with 10  $\mu$ M isoproterenol, 10  $\mu$ M propranolol, or 10  $\mu$ M bucindolol.  $\beta$ Arrestin knockdown was assessed by subjecting cell lysates to Western blot using the anti- $\beta$ arrestin2 (H9) antibody recognizing both  $\beta$ arrestin isoforms (inset). ERK1/2 activation was detected and quantified as described in Fig. 1C. Data represent the mean  $\pm$  S.E. of at least three independent experiments.

gaged either  $\beta$ arrestin or the G protein, respectively (Gesty-Palmer et al., 2006). Likewise, although binding of angiotensin-II to its type 1 receptor AT1R engaged both  $G_q$  and  $\beta$ arrestin, a synthetic angiotensin-II analog stimulated MAPK in an exclusively  $\beta$ arrestin-dependent manner (Wei et al., 2003). In addition, in a recent study, two  $\beta$ -adrenergic ligands, cyclopentylbutanephine and isoproterenol, were found to rely differentially on  $\beta$ arrestin to activate ERK1/2 (Drake et al., 2008). The assessment in the present study of two signaling responses (i.e., AC and MAPK) allowed to further refine the level of selectivity by distinguishing two compounds that share the same  $G_i$ -independent MAPK signaling signature (bucindo-

lol and propranolol), but they have opposite efficacies (i.e., agonist versus inverse agonist) when considering AC activity.

Although ERK1/2 activation can lie downstream of AC stimulation (Vossler et al., 1997; Grewal et al., 2000), our results clearly indicate that the two pathways can be independently regulated in HEK293 cells, as demonstrated previously for the A2-adenosine receptor (Seidel et al., 1999). Indeed, even though isoproterenol and bucindolol are agonists for the two signaling systems, their ability to activate ERK1/2 was found to be independent of their positive coupling to cAMP generation (Fig. 2). This independence of the ERK1/2 activation from cAMP production is further substan-



**Fig. 6.** Src and MEK kinases are involved in the ERK1/2 signaling cascades promoted by the three ligands. Serum-starved HEK293 cells stably expressing the  $\beta$ 1AR were pretreated or not for 1 h at 37°C with the Src inhibitor PP2 (10  $\mu$ M) (A) or with the MEK inhibitor PD98059 (50  $\mu$ M) (B) before stimulation with 10  $\mu$ M isoproterenol (4 min), 10  $\mu$ M propranolol, or 10  $\mu$ M bucindolol (2 min), or 1 ng/ml EGF (10 min; see insets). ERK1/2 activation was detected and quantified as described in Fig. 1C. Data represent the mean  $\pm$  S.E. of at least three independent experiments. For A and B, statistical significance of the differences was assessed using one-way analysis of variance and post hoc Bonferroni test; \*\*,  $p < 0.01$  and \*\*\*,  $p < 0.001$ .




tiated by the fact that propranolol, which acts as an inverse agonist for AC, stimulated the ERK1/2 activity to the same extent than bucindolol. The observation that propranolol acts as an inverse agonist for AC but as a partial agonist for ERK1/2 activities clearly demonstrates the occurrence of functional ligand selectivity at the  $\beta$ 1AR.

Functional selectivity was also revealed by the distinct ERK1/2 cascades promoted by the three  $\beta$ -adrenergic ligands. Indeed, inactivation of  $G_i$  by PTX treatment partially inhibited isoproterenol- but not bucindolol- or propranolol-stimulated ERK1/2. Such ligand-specific sensitivity to chemical  $G_i$  knockdown suggests that only isoproterenol can induce  $\beta$ 1AR coupling to  $G_i$ . This differential involvement of  $G_i$  in the  $\beta$ 1AR-stimulated ERK1/2 cascades was further confirmed by the observation that isoproterenol but not bucindolol or propranolol promoted  $G_i$  activation, as reflected by the decrease in the BRET signal detected between  $G\alpha_{i1}$  and  $G\gamma_2$ . The involvement of  $G_i$  in the isoproterenol-stimulated ERK1/2 activation has been proposed previously for the  $\beta$ 1AR in Chinese hamster ovary cells (Martin et al., 2004). As is often the case for  $G_i$ -dependent activation of ERK1/2 (Crespo et al., 1994; Koch et al., 1994; Della Rocca et al., 1997), the isoproterenol-stimulated MAPK activation involves  $G\beta\gamma$ , as indicated by the inhibitory action of the  $G\beta\gamma$  scavenger T8 $\beta$ ARKctail. Given that chronic CTX treatment should inhibit  $G\beta\gamma$  activation arising from  $G\alpha_s$  stimulation, the lack of CTX inhibitory effect on the isoproterenol-stimulated

ERK1/2 activity suggests that  $G\beta\gamma$  originating from  $G_i$  but not  $G_s$  account for the MAPK activation.

Among the three ligands tested, only isoproterenol led to ERK1/2 activation through the engagement of both  $G_i$ -dependent and -independent pathways. Note that these two pathways require the activation of Src tyrosine kinases for the ERK1/2 response, indicating a convergence of all cascades on a single integrator. Having several distinct cascades converging on the MAPK could have many important biological implications. For one thing, the existence of more than one pathway regulating a common cell signal generates additional intermediates that offer more control and check points to fine tune the response. Obvious consequences of such signaling convergence could include changes in the intensity and spatiotemporal characteristic of the response. For example, the greater maximal ERK1/2 response observed for isoproterenol compared with bucindolol and propranolol could reflect the convergence of the  $G_i$ -dependent and -independent pathways. This hypothesis is supported by the observation that PTX treatment blunted the isoproterenol-stimulated response to a level equivalent to that reached upon bucindolol and propranolol stimulation. Removing the  $G_i$  component also affected the kinetics of the isoproterenol-mediated response, consistently shifting the peak stimulation from 4 to 2 min. It follows that the time course and amplitude of the isoproterenol-stimulated response upon  $G_i$  inactivation becomes almost identical to those of bucindolol and propranolol,



**Fig. 7.** Linking receptor conformational changes to signaling efficacy. BRET was measured in cells coexpressing  $\beta$ 1AR-hRluc and GFP10-G $\gamma_2$  in the presence of untagged  $G\alpha_{i1}$  (A) or  $\beta$ 1AR-GFP10 and  $G\alpha_{i1}$ -91hRluc (B), and stimulated or not with 10  $\mu$ M isoproterenol (Iso), 10  $\mu$ M bucindolol (Buc), or 10  $\mu$ M propranolol (Prop). Results are expressed as the difference in the BRET signal measured in the presence or absence of the indicated ligands. A schematic representation of the proteins used is shown (insets). Data represent the mean  $\pm$  S.E. of at least three independent experiments. For A and B, one-way analysis of variance followed by Dunnett's test was used to determine statistically significant differences from basal; \*\*\*,  $p < 0.001$ .

indicating a common  $G_i$ -independent pathway for the three ligands. Although the downstream consequences of the differences in MAPK activation kinetics were not investigated in the present study, different temporal patterns of ERK1/2 activation have previously been suggested to have distinct consequences on gene regulation and cell proliferation (Murphy et al., 2004; Santos et al., 2007). Multicomponent kinetics of GPCR-promoted ERK1/2 activation have been reported previously for several receptors, including parathyroid hormone receptor,  $\beta$ 2-adrenergic receptor, and angiotensin II receptor (Ahn et al., 2004; Gesty-Palmer et al., 2006; Shenoy et al., 2006). In these studies, the early activation phase has been attributed to G protein-dependent pathways, whereas  $\beta$ arrestins contribution has been linked to the late phase. However, the kinetics observed for those receptors were different from the kinetics detected herein for the  $\beta$ 1AR, with the late phase peaking at much longer times than 4 min. Consistent with this difference, a  $\beta$ arrestin dominant-negative mutant and cellular depletion of  $\beta$ arrestins by siRNAs failed to inhibit the isoproterenol-, bucindolol-, and propranolol-stimulated ERK1/2, indicating that  $\beta$ arrestin is not involved in the  $\beta$ 1AR-promoted MAPK activation by these three compounds. This may not be surprising given the low affinity of  $\beta$ arrestins for the  $\beta$ 1AR (Shiina et al., 2000). The phase peaking at 4 min in our study was found to be  $G_i$ -dependent, and it most likely corresponds to the G protein-dependent early phase observed in previous studies. Our results thus reveal the existence of an even earlier phase (peaking at 2 min), which is independent of both G proteins and  $\beta$ arrestin. This does not rule out the possibility that  $\beta$ 1AR could promote  $\beta$ arrestin-dependent ERK1/2 activity upon stimulation by different ligands. Indeed, in a recent study, Noma et al. (2007) reported that the selective  $\beta$ 1AR agonist dobutamine can activate ERK1/2 in a  $\beta$ arrestin-dependent manner, further supporting the notion of ligand directed signaling. The existence of a G protein and  $\beta$ arrestin independent, but Src-dependent ERK1/2 activation pathway promoted by bucindolol and propranolol in our study, has also been recently revealed for the 5-hydroxytryptamine 4 receptors (Barthet et al., 2007)

Taken together, our results clearly demonstrate the occurrence of functional selectivity of the  $\beta$ 1AR/ligand pairs not only toward the two signaling outputs studied (i.e., AC and MAPK) but also between two distinct pathways converging on the same output (i.e., MAPK). This implies that several distinct receptor conformations can be selectively promoted by different ligands. In line with this notion, BRET measured between the carboxyl tail of the  $\beta$ 1AR and either  $G_{\alpha_{11}}$  or  $G_{\gamma_2}$  revealed distinct conformational rearrangements of the receptor/G protein complex upon activation with the different ligands. Conformational rearrangements induced by isoproterenol could be readily distinguished from those promoted by either bucindolol or propranolol, the orientation of the BRET changes being opposite. Previous biophysical studies monitoring the fluorescent properties of intramolecular probes within purified receptors demonstrated that different ligands can induce distinct conformations of the receptor (Ghanouni et al., 2001; Swaminath et al., 2005). Our findings extend such observation to living cells and start establishing correlation between specific conformational changes promoted by ligands and their ability to selectively engage distinct signaling pathways. However, not all distinct conforma-

tional changes could be detected by the BRET biosensor used. Indeed, given that bucindolol and propranolol have opposite efficacy toward AC, they should promote distinct structural rearrangements. Yet, this difference could not be detected, with both ligands promoting a decrease in BRET between the receptor and the G protein subunits. This is not surprising when considering that BRET can only monitor the changes in distance between two specific points in the complex. Thus, the lack of difference in ligand-promoted BRET only indicates that local conformational changes maybe shared by the ligands, but it does not allow to rule out the occurrence of different conformational rearrangement in spatially distinct domains of the receptor. Additional biosensors monitoring structural rearrangements from multiple view points should, in the future, allow to precisely link specific local receptor conformations to distinct signaling pathways.

#### Acknowledgments

We are grateful to Dr. Monique Lagacé for critical reading of the manuscript.

#### References

- Ahn S, Nelson CD, Garrison TR, Miller WE, and Lefkowitz RJ (2003) Desensitization, internalization, and signaling functions of beta-arrestins demonstrated by RNA interference. *Proc Natl Acad Sci U S A* **100**:1740–1744.
- Ahn S, Shenoy SK, Wei H, and Lefkowitz RJ (2004) Differential kinetic and spatial patterns of  $\beta$ -arrestin and G protein-mediated ERK activation by the angiotensin II receptor. *J Biol Chem* **279**:35518–35525.
- Barthet G, Framery B, Gaven F, Pellissier L, Reiter E, Claeysen S, Bockaert J, and Dumuis A (2007) 5-Hydroxytryptamine 4 receptor activation of the extracellular signal-regulated kinase pathway depends on Src activation but not on G protein or beta-arrestin signaling. *Mol Biol Cell* **18**:1979–1991.
- Bockaert J, Fagni L, Dumuis A, and Marin P (2004) GPCR interacting proteins (GIP). *Pharmacol Ther* **103**:203–221.
- Cao W, Luttrell LM, Medvedev AV, Pierce KL, Daniel KW, Dixon TM, Lefkowitz RJ, and Collins S (2000) Direct binding of activated c-Src to the  $\beta$ 3-adrenergic receptor is required for MAP kinase activation. *J Biol Chem* **275**:38131–38134.
- Charest PG, Oligny-Longpre G, Bonin H, Azzi M, and Bouvier M (2007) The V2 vasopressin receptor stimulates ERK1/2 activity independently of heterotrimeric G protein signalling. *Cell Signal* **19**:32–41.
- Crespo P, Cachero TG, Xu N, and Gutkind JS (1995) Dual effect of  $\beta$ -adrenergic receptors on mitogen-activated protein kinase. Evidence for a  $\beta$ -dependent activation and a Gas-cAMP-mediated inhibition. *J Biol Chem* **270**:25259–25265.
- Crespo P, Xu N, Simonds WF, and Gutkind JS (1994) Ras-dependent activation of MAP kinase pathway mediated by G-protein beta gamma subunits. *Nature* **369**:418–420.
- Daaka Y, Luttrell LM, and Lefkowitz RJ (1997) Switching of the coupling of the beta2-adrenergic receptor to different G proteins by protein kinase A. *Nature* **390**:88–91.
- DeFea KA, Vaughn ZD, O'Bryan EM, Nishijima D, Dery O, and Bunnett NW (2000a) The proliferative and antiapoptotic effects of substance P are facilitated by formation of a beta-arrestin-dependent scaffolding complex. *Proc Natl Acad Sci U S A* **97**:11086–11091.
- DeFea KA, Zalevsky J, Thoma MS, Dery O, Mullins RD, and Bunnett NW (2000b) beta-Arrestin-dependent endocytosis of proteinase-activated receptor 2 is required for intracellular targeting of activated ERK1/2. *J Cell Biol* **148**:1267–1281.
- Della Rocca GJ, van Biesen T, Daaka Y, Luttrell DK, Luttrell LM, and Lefkowitz RJ (1997) Ras-dependent mitogen-activated protein kinase activation by G protein-coupled receptors. Convergence of  $G_i$ - and  $G_q$ -mediated pathways on calcium/calmodulin, Pyk2, and Src kinase. *J Biol Chem* **272**:19125–19132.
- Drake MT, Violin JD, Whalen EJ, Wisler JW, Shenoy SK, and Lefkowitz RJ (2008)  $\beta$ -Arrestin-biased agonism at the  $\beta$ 2-adrenergic receptor. *J Biol Chem* **283**:5669–5676.
- Galandrin S and Bouvier M (2006) Distinct signaling profiles of  $\beta$ 1 and  $\beta$ 2 adrenergic receptor ligands toward adenylyl cyclase and mitogen-activated protein kinase reveals the pluridimensionality of efficacy. *Mol Pharmacol* **70**:1575–1584.
- Galandrin S, Oligny-Longpre G, and Bouvier M (2007) The evasive nature of drug efficacy: implications for drug discovery. *Trends Pharmacol Sci* **28**:423–430.
- Galés C, Rebois RV, Hogue M, Trieu P, Breit A, Hebert TE, and Bouvier M (2005) Real-time monitoring of receptor and G-protein interactions in living cells. *Nat Methods* **2**:177–184.
- Galés C, Van Durm JJ, Schaak S, Pontier S, Percherancier Y, Audet M, Paris H, and Bouvier M (2006) Probing the activation-promoted structural rearrangements in preassembled receptor-G protein complexes. *Nat Struct Mol Biol* **13**:778–786.
- Gesty-Palmer D, Chen M, Reiter E, Ahn S, Nelson CD, Wang S, Eckhardt AE, Cowan CL, Spurney RF, Luttrell LM, et al. (2006) Distinct  $\beta$ -arrestin- and G protein-dependent pathways for parathyroid hormone receptor-stimulated ERK1/2 activation. *J Biol Chem* **281**:10856–10864.
- Ghanouni P, Grzycki Z, Steenhuis JJ, Lee TW, Farrens DL, Lakowicz JR, and Kobilka BK (2001) Functionally different agonists induce distinct conformations in

- the G protein coupling domain of the  $\beta 2$  adrenergic receptor. *J Biol Chem* **276**:24433–24436.
- Grewal SS, Fass DM, Yao H, Ellig CL, Goodman RH, and Stork PJ (2000) Calcium and cAMP signals differentially regulate cAMP-responsive element-binding protein function via a Rap1-extracellular signal-regulated kinase pathway. *J Biol Chem* **275**:34433–34441.
- Kenakin T (2007) Collateral efficacy in drug discovery: taking advantage of the good (allosteric) nature of 7TM receptors. *Trends Pharmacol Sci* **28**:407–415.
- Koch WJ, Hawes BE, Allen LF, and Lefkowitz RJ (1994) Direct evidence that Gi-coupled receptor stimulation of mitogen-activated protein kinase is mediated by G beta gamma activation of p21ras. *Proc Natl Acad Sci U S A* **91**:12706–12710.
- Luttrell LM (2005) Composition and function of G protein-coupled receptor signalosomes controlling mitogen-activated protein kinase activity. *J Mol Neurosci* **26**:253–264.
- Luttrell LM, Ferguson SS, Daaka Y, Miller WE, Maudsley S, Della Rocca GJ, Lin F, Kawakatsu H, Owada K, Luttrell DK, et al. (1999) beta-Arrestin-dependent formation of beta2 adrenergic receptor-Src protein kinase complexes. *Science* **283**:655–661.
- Luttrell LM, Roudabush FL, Choy EW, Miller WE, Field ME, Pierce KL, and Lefkowitz RJ (2001) Activation and targeting of extracellular signal-regulated kinases by beta-arrestin scaffolds. *Proc Natl Acad Sci U S A* **98**:2449–2454.
- Martin NP, Whalen EJ, Zamah MA, Pierce KL, and Lefkowitz RJ (2004) PKA-mediated phosphorylation of the beta1-adrenergic receptor promotes Gs/Gi switching. *Cell Signal* **16**:1397–1403.
- McDonald PH, Chow CW, Miller WE, Laporte SA, Field ME, Lin FT, Davis RJ, and Lefkowitz RJ (2000) beta-Arrestin 2: a receptor-regulated MAPK scaffold for the activation of JNK3. *Science* **290**:1574–1577.
- Mercier JF, Salahpour A, Angers S, Breit A, and Bouvier M (2002) Quantitative assessment of  $\beta 1$ - and  $\beta 2$ -adrenergic receptor homo- and heterodimerization by bioluminescence resonance energy transfer. *J Biol Chem* **277**:44925–44931.
- Miller WE, Maudsley S, Ahn S, Khan KD, Luttrell LM, and Lefkowitz RJ (2000) beta-arrestin1 interacts with the catalytic domain of the tyrosine kinase c-SRC. Role of beta-arrestin1-dependent targeting of c-SRC in receptor endocytosis. *J Biol Chem* **275**:11312–11319.
- Murphy LO, MacKeigan JP, and Blenis J (2004) A network of immediate early gene products propagates subtle differences in mitogen-activated protein kinase signal amplitude and duration. *Mol Cell Biol* **24**:144–153.
- Neves SR, Ram PT, and Iyengar R (2002) G protein pathways. *Science* **296**:1636–1639.
- Noma T, Lemaire A, Naga Prasad SV, Barki-Harrington L, Tilley DG, Chen J, Le Corvoisier P, Violin JD, Wei H, Lefkowitz RJ, et al. (2007)  $\beta$ -Arrestin-mediated beta1-adrenergic receptor transactivation of the EGFR confers cardioprotection. *J Clin Invest* **117**:2445–2458.
- Petaja-Repo UE, Hogue M, Laperriere A, Walker P, and Bouvier M (2000) Export from the endoplasmic reticulum represents the limiting step in the maturation and cell surface expression of the human delta opioid receptor. *J Biol Chem* **275**:13727–13736.
- Reeves PJ, Thurmond RL, and Khorana HG (1996) Structure and function in rhodopsin: high level expression of a synthetic bovine opsin gene and its mutants in stable mammalian cell lines. *Proc Natl Acad Sci U S A* **93**:11487–11492.
- Santos SD, Verveer PJ, and Bastiaens PI (2007) Growth factor-induced MAPK network topology shapes Erk response determining PC-12 cell fate. *Nat Cell Biol* **9**:324–330.
- Seidel MG, Klingler M, Freissmuth M, and Holler C (1999) Activation of mitogen-activated protein kinase by the A(2A)-adenosine receptor via a rap1-dependent and via a p21(ras)-dependent pathway. *J Biol Chem* **274**:25833–25841.
- Shenoy SK, Drake MT, Nelson CD, Houtz DA, Xiao K, Madabushi S, Reiter E, Premont RT, Lichtarge O, and Lefkowitz RJ (2006)  $\beta$ -Arrestin-dependent, G protein-independent ERK1/2 activation by  $\beta 2$  adrenergic receptor. *J Biol Chem* **281**:1261–1273.
- Shiina T, Kawasaki A, Nagao T, and Kurose H (2000) Interaction with  $\beta$ -arrestin determines the difference in internalization behavior between  $\beta 1$ - and  $\beta 2$ -adrenergic receptors. *J Biol Chem* **275**:29082–29090.
- Swaminath G, Deupi X, Lee TW, Zhu W, Thian FS, Kobilka TS, and Kobilka B (2005) Probing the  $\beta 2$  adrenoceptor binding site with catechol reveals differences in binding and activation by agonists and partial agonists. *J Biol Chem* **280**:22165–22171.
- Vossler MR, Yao H, York RD, Pan MG, Rim CS, and Stork PJ (1997) cAMP activates MAP kinase and Elk-1 through a B-Raf- and Rap1-dependent pathway. *Cell* **89**:73–82.
- Wei H, Ahn S, Shenoy SK, Karnik SS, Hunyady L, Luttrell LM, and Lefkowitz RJ. (2003) Independent beta-arrestin 2 and G protein-mediated pathways for angiotensin II activation of extracellular signal-regulated kinases 1 and 2. *Proc Natl Acad Sci U S A* **100**:10782–10787.

---

**Address correspondence to:** Dr. Céline Galès, Institut National de la Santé et de la Recherche Médicale U858-I2MR-Equipe 8, 1 avenue Jean Poulhès, BP 84225, 31432 Toulouse Cedex 4, France. E-mail: celine.gales@toulouse.inserm.fr

---